Virginia Kaklamani, MD, University of Texas Health Science Center

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

ByVirginia Kaklamani, MD, University of Texas Health Science Center

June 19th 2023

Closing out her discussion on HER2+ metastatic breast cancer, expert oncologist Virginia Kaklamani, MD, DSc, highlights ongoing unmet needs future directions in care.

Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer

ByVirginia Kaklamani, MD, University of Texas Health Science Center

June 19th 2023

Comprehensive insight on acquired resistance to HER2-targeted therapy in metastatic breast cancer, and how treatments can be selected and sequenced thereafter.

Role of Brain Metastases and Quality of Life in Treatment Decisionmaking

ByVirginia Kaklamani, MD, University of Texas Health Science Center

June 12th 2023

Virginia Kaklamani, MD, DSc, shares her perspective on the roles that brain metastases and quality of life play, respectively, in selecting treatment for HER2+ mBC.

Factors in Selecting Third-Line Therapy for HER2+ Metastatic Breast Cancer

ByVirginia Kaklamani, MD, University of Texas Health Science Center

June 12th 2023

Focused discussion on factors that help inform treatment selection for patients with HER2+ metastatic breast cancer in the third-line setting.

Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

ByVirginia Kaklamani, MD, University of Texas Health Science Center

June 5th 2023

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

Impact of Recent Clinical Data on Treatment for HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Treatment Choice for Patient Relapsing With Brain Metastases

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2CLIMB: Brain Metastases Data

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Guidelines and Approaches to HER2 Testing for Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

ByVirginia Kaklamani, MD, University of Texas Health Science Center

December 31st 2014

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Articles by Virginia Kaklamani, MD, University of Texas Health Science Center

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer

Role of Brain Metastases and Quality of Life in Treatment Decisionmaking

Factors in Selecting Third-Line Therapy for HER2+ Metastatic Breast Cancer

Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

Impact of Recent Clinical Data on Treatment for HER2+ MBC

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

Treatment Choice for Patient Relapsing With Brain Metastases

HER2CLIMB: Brain Metastases Data

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

HER2+ Early-Stage Breast Cancer

Guidelines and Approaches to HER2 Testing for Breast Cancer

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

Latest Updated Articles

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL